Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Benign Prostatic Hypertrophy | Research

Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia

Authors: Deusdedit Tusubira, Patrick M. Aja, Jonasi Munezero, Frank Ssedyabane, Nathim Namale, Josiah E. Ifie, Peter C. Agu, Clement O. Ajayi, Joash Okoboi

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Introduction

This study was motivated by the increasing global incidence of benign prostatic hyperplasia (BPH) and the promising potential of nutraceuticals as complementary therapies in ameliorating its burden. We report the safety profile of C. esculenta tuber extracts, a novel nutraceutical in benign prostate hyperplasia in a rat model.

Methods

In this study, forty-five male albino rats were randomly assigned to 9 groups of 5 rats each. Group 1 (normal control) received olive oil and normal saline. Group 2 (BPH untreated group) received 3 mg/kg of testosterone propionate (TP) and normal saline, and group 3 (positive control) received 3 mg/kg of TP and 5 mg/kg of finasteride. Treatment groups 4, 5, 6, 7, 8, and 9 received 3 mg/kg of TP and a middle dose (200 mg/kg) of LD50 of ethanol crude tuber extract of C. esculenta (ECTECE) or hexane, dichloromethane, butanone, ethyl acetate and aqueous fractions of ECTECE respectively for a period of 28 days.

Results

The negative controls showed a significant (p < 0.05) increase in mean relative prostate weight (approximately 5 times) as well as a reduction in relative testes weight (approximately 1.4 times less). There was no significant (p > 0.05) difference in the mean relative weights of most vital organs: liver, kidneys, and heart. This was also observed in hematological parameters: RBC, hemoglobin, HCT, MCV, MCH, MCHC, and platelets counts. In general, we note that the effects of the well-established drug finasteride on the biochemical parameters and histology of selected organs are comparable to those of C. esculenta fractions.

Conclusion

This study demonstrates that C. esculenta tuber extracts provide potentially safe nutraceutical if applied in the management of benign prostate hyperplasia based on a rat model.
Literature
1.
Global regional. National age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet (London England). 2018;392(10159):1684–735.CrossRef
2.
Chughtai B, Forde JC, Thomas DDM, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat reviews Disease primers. 2016;2(1):1–15.
3.
Sohlberg EM, Thomas IC, Yang J, Kapphahn K, Daskivich TJ, Skolarus TA, Shelton JB, Makarov DV, Bergman J, Bang CK, et al. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urol Oncol. 2020;38(9):734e731–734e710.CrossRef
4.
Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. 2021, 127(6):722–8.
5.
6.
Gossel TA, Wuest JR. New drugs of 2004 for treatment of benign prostatic hyperplasia: Avodart and Uroxatal. Contin Educ Pharm. 2004;22:1–4.
7.
Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134–40.PubMedCrossRef
8.
Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr, Terris MK, Klaassen Z. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational Androl Urol. 2019;8(5):529.CrossRef
9.
Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, Tettey Y, Adjei A, Jadallah S, Li Y, et al. Prevalence of BPH and lower urinary tract symptoms in West Africans. Prostate Cancer Prostatic Dis. 2012;15(2):170–6.PubMedCrossRef
10.
Yeboah ED, PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER IN AFRICANS AND AFRICANS IN THE DIASPORA. J West Afr Coll Surg. 2016;6(4):1–30.PubMedPubMedCentral
11.
Peter N, Michael C. Benign Prostatic Hyperplasia (BPH) in an elderly ugandan male. MMJ 2014, 46(1).
12.
Pais P. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5α-reductase II. Adv therapy. 2010;27(8):555–63.CrossRef
13.
Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin. 2011;95(1):87–100.
14.
Bajunirwe F, Stothers L, Berkowitz J, Macnab AJ. Prevalence estimates for lower urinary tract symptom severity among men in Uganda and sub-saharan Africa based on regional prevalence data. Can Urol Association journal = Journal de l’Association des urologues du Can. 2018;12(11):E447–e452.
15.
Corona G, Rastrelli G, Maseroli E, Balercia G, Sforza A, Forti G, Mannucci E, Maggi M. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Investig. 2012;35(10):915–20.
16.
Ogunbiyi OJ. Impact of health system challenges on prostate cancer control: health care experiences in Nigeria. Infect Agents Cancer. 2011;6(2):5.CrossRef
17.
Yu Z-J, Yan H-L, Xu F-H, Chao H-C, Deng L-H, Xu X-D, Huang J-B, Zeng T. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020;11:658.PubMedPubMedCentralCrossRef
18.
Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the prostate research on Behaviour and Education (PROBE) Survey. Int J Clin Pract. 2008;62(1):18–26.PubMedCrossRef
19.
Ückert S, Kedia GT, Tsikas D, Simon A, Bannowsky A, Kuczyk MA. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World J Urol. 2020;38(6):1423–35.PubMedCrossRef
20.
Dunn MW, Kazer MW. Prostate cancer overview. In: Seminars in oncology nursing: 2011: Elsevier; 2011: 241–50.
21.
Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr Opin Urol. 2014;24(1):21–8.PubMedCrossRef
22.
Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015;22(Suppl 1):7–17.PubMed
23.
Saka SA, Yusuf AA, Campus S. Drug therapy problem in elderly outpatients with benign prostatic hyperplasia. West Afr J Pharm. 2021;32(1):33–44.
24.
Eleazu C, Eleazu K, Kalu W. Management of benign prostatic hyperplasia: could dietary polyphenols be an alternative to existing therapies? Front Pharmacol. 2017;8:234.PubMedPubMedCentralCrossRef
25.
Cicero AFG, Allkanjari O, Busetto GM, Cai T, Larganà G, Magri V, Perletti G, Robustelli Della Cuna FS, Russo GI, Stamatiou K et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Archivio italiano di urologia andrologia: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2019, 91(3).
26.
Curtis Nickel J, Shoskes D, Roehrborn CG, Moyad M. Nutraceuticals in prostate disease: the urologist’s role. Rev Urol. 2008;10(3):192–206.PubMedPubMedCentral
27.
Talwana H, Serem A, Ndabikunze B, Nandi J, Tumuhimbise R, Kaweesi T, Chumo C, Palapala VA. Production Status and Prospects of Cocoyam (Colocasia esculenta L. Schott.) in East Africa. 2009.
28.
Otekunrin OA, Sawicka B, Adeyonu AG, Otekunrin OA, Rachoń L. Cocoyam [Colocasia esculenta (L.) Schott]: exploring the production, Health and Trade Potentials in Sub-Saharan Africa. Sustainability. 2021;13(8):4483.CrossRef
29.
Prajapati R, Kalariya M, Umbarkar R, Parmar S, Sheth N. Colocasia esculenta: a potent indigenous plant. Int J Nutr Pharmacol Neurol Dis. 2011;1(2):90.CrossRef
30.
Mitsunari K, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Harada J, Kondo T, Matsuda T, Ohba K, Sakai H. Pharmacological Effects and potential clinical usefulness of polyphenols in Benign Prostatic Hyperplasia. Molecules. 2021;26(2):450.PubMedPubMedCentralCrossRef
31.
Keerthy S, Joshi KH. The pharmacological importance of Colocasia esculenta Linn: a review. J Pharmacognosy Phytochemistry. 2019;8(6):1945–8.
32.
Brown AC, Reitzenstein JE, Liu J, Jadus MR. The anti-cancer effects of poi (Colocasia esculenta) on colonic adenocarcinoma cells in vitro. Phytother Res. 2005;19(9):767–71.PubMedCrossRef
33.
Kalariya M, Prajapati R, Parmar SK, Sheth N. Effect of hydroalcoholic extract of leaves of Colocasia esculenta on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Pharm Biol. 2015;53(8):1239–42.PubMedCrossRef
34.
Islam MH, Mostafa MN, Rahmatullah M. Antihyperglycemic activity of methanolic extracts of corms of Colocasia esculenta var esculenta. Eur J Pharm Med Res. 2018;5(3):129–32.
35.
Tripathi AK, Kohli S. Phytochemical screening and evaluation of antidiabetic activity of Colocasia esculenta (L) leaves on STZ induced diabetic rats. Adv Pharmacol Toxicol. 2013;14(2):1.
36.
Eleazu CO, Okafor PN, Ifeoma I. Biochemical basis of the use of cocoyam (Colocassia esculenta L.) in the dietary management of diabetes and its complications in streptozotocin induced diabetes in rats. Asian Pac J Trop Disease. 2014;4:705–S711.CrossRef
37.
Shithi S, Mohammed R. Antihyperglycemic and antinociceptive activities of methanolic extract of Colocasia esculenta (L.) Schott stems: a preliminary study. American-Eurasian J Sustainable Agric. 2013;7(4):314–9.
38.
Eleazu C. Characterization of the natural products in cocoyam (Colocasia esculenta) using GC–MS. Pharm Biol. 2016;54(12):2880–5.PubMedCrossRef
39.
Nyonseu Nzebang DC, Ngaha Njila MI, Bend EF, Oundoum Oundoum PC, Koloko BL, Bogning Zangueu C, Belle Ekedi P, Sameza M, Massoma Lembè D. Evaluation of the toxicity of Colocasia esculenta (Aracaceae): preliminary study of leaves infected by Phytophthora colocasiae on wistar albinos rats. Biomed pharmacotherapy = Biomedecine pharmacotherapie. 2018;99:1009–13.CrossRef
40.
Eleazu K, Maduabuchi Aja P, Eleazu CO. Cocoyam (Colocasia esculenta) modulates some parameters of testosterone propionate-induced rat model of benign prostatic hyperplasia. Drug Chem Toxicol 2021:1–11.
41.
Stowell LI, Sharman LE, Hamel K. An enzyme-linked immunosorbent assay (ELISA) for prostate-specific antigen. Forensic Sci Int. 1991;50(1):125–38.PubMedCrossRef
42.
Feldman AT, Wolfe D. Tissue processing and hematoxylin and eosin staining. Methods in molecular biology (Clifton NJ). 2014;1180:31–43.CrossRef
43.
Omotoso Abayomi E, Kenneth E, Mkparu K. Chemometric profiling of methanolic leaf extract of Cnidoscolus aconitifolius (Euphorbiaceae) using UV-VIS, FTIR and GC-MS techniques. J Med Plants Res. 2014;2(1):6–12.
44.
Eleazu CO. Characterization of the natural products in cocoyam (Colocasia esculenta) using GC–MS. Pharm Biol. 2016;54(12):2880–5.PubMedCrossRef
45.
Kalu W, Okafor P, Ijeh I, Eleazu C. Effect of kolaviron, a biflavanoid complex from Garcinia kola on some biochemical parameters in experimentally induced benign prostatic hyperplasic rats. Biomed Pharmacother. 2016;83:1436–43.PubMedCrossRef
46.
Eleazu CO, Iroaganachi M, Eleazu K. Ameliorative potentials of cocoyam (Colocasia esculenta L.) and unripe plantain (Musa paradisiaca L.) on the relative tissue weights of streptozotocin-induced diabetic rats. Journal of diabetes research 2013, 2013.
47.
Azubuike NC, Onwukwe OS, Onyemelukwe AO, Maduakor UC, Ifeorah IM, Okwuosa CN, Achukwu PU. Impact of Colocasia esculenta extract and fractions on high-fat diet-induced changes in body weight, adipose tissue and liver of rats. Pak J Pharm Sci 2018.
48.
Van ROIJENJH, OOMS MP, WEBER RF, BRINKMANN AO, GROOTEGOED JA, VREEBURG JT. Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881). J Androl. 1997;18(1):51–61.
49.
Princewill-Ogbonna IL, Ihedioha S, Ijeoma SN. Hematological and liver/Kidney histology of rats feed with cocoyam (Colocasia esculenta L). Contemp J Empir Res. 2016;2(3):271–87.
Metadata
Title
Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia
Authors
Deusdedit Tusubira
Patrick M. Aja
Jonasi Munezero
Frank Ssedyabane
Nathim Namale
Josiah E. Ifie
Peter C. Agu
Clement O. Ajayi
Joash Okoboi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04018-4

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Correction

Correction: Network pharmacology and molecular docking study for biological pathway detection of cytotoxicity of the yellow jasmine flowers

Research

Management of post-traumatic stress disorder symptoms by yoga: an overview

Research

Preclinical evaluation of antimalarial activity of CPF-1 formulation as an alternative choice for the treatment of malaria

Research

The aqueous extract of Artemisia Absinthium L. stimulates HO-1/MT-1/Cyp450 signaling pathway via oxidative stress regulation induced by aluminium oxide nanoparticles (α and γ) animal model

Research

Total flavonoids of Chrysanthemum indicum L inhibit acute pancreatitis through suppressing apoptosis and inflammation

Research

The effects of melissa officinalis on depression and anxiety in type 2 diabetes patients with depression: a randomized double-blinded placebo-controlled clinical trial